Azitra, Inc. Files S-1 for Public Offering
Ticker: AZTR · Form: S-1 · Filed: Jul 15, 2024 · CIK: 1701478
Sentiment: neutral
Topics: ipo, registration-statement, pharmaceuticals
TL;DR
Azitra Inc. just filed an S-1, looks like they're gearing up for an IPO. Keep an eye on this one.
AI Summary
Azitra, Inc. filed an S-1 registration statement on July 15, 2024, to register securities for public offering. The company, incorporated in Delaware with its principal executive offices at 21 Business Park Drive, Branford, CT 06405, operates in the Pharmaceutical Preparations sector (SIC code 2834). The filing indicates a potential public offering, though specific dollar amounts and dates for the offering are not detailed in this initial S-1 document.
Why It Matters
This S-1 filing signals Azitra, Inc.'s intention to raise capital through a public offering, which could fund its pharmaceutical development and operations.
Risk Assessment
Risk Level: medium — As an S-1 filing, it indicates a company is preparing for an initial public offering, which inherently carries market and execution risks.
Key Numbers
- 2834 — SIC Code (Pharmaceutical Preparations industry)
- 464478536 — IRS Number (Company identification)
- 333-280806 — SEC File Number (Registration tracking)
Key Players & Entities
- Azitra, Inc. (company) — Registrant
- 21 Business Park Drive, Branford, CT 06405 (location) — Principal Executive Offices
- Francisco D. Salva (person) — Agent for Service
- Daniel K. Donahue, Esq. (person) — Counsel
- Greenberg Traurig, LLP (company) — Legal Counsel
- Barry Grossman, Esq. (person) — Counsel
- Matthew Bernstein, Esq. (person) — Counsel
- Justin Grossman, Esq. (person) — Counsel
- Ellenoff Grossman & Schole (company) — Legal Counsel
FAQ
What is the purpose of this S-1 filing by Azitra, Inc.?
Azitra, Inc. filed this S-1 registration statement to register securities for a public offering, indicating their intent to raise capital.
When was this S-1 filing submitted to the SEC?
The S-1 filing was submitted to the U.S. Securities and Exchange Commission on July 15, 2024.
Where are Azitra, Inc.'s principal executive offices located?
Azitra, Inc.'s principal executive offices are located at 21 Business Park Drive, Suite 6, Branford, CT 06405.
What industry does Azitra, Inc. operate in, according to its SIC code?
Azitra, Inc. operates in the Pharmaceutical Preparations industry, as indicated by its SIC code 2834.
Who is listed as the agent for service for Azitra, Inc. in this filing?
Francisco D. Salva is listed as the agent for service for Azitra, Inc.
Filing Stats: 4,592 words · 18 min read · ~15 pages · Grade level 14.1 · Accepted 2024-07-15 06:21:55
Key Financial Figures
- $0.0001 — ne share of our common stock, par value $0.0001 per share (the “common stock&rdqu
- $3 — public offering price for each Unit is $3.21, which was the last reported sale pr
- $3.21 — of 3.21 (assuming an offering price of $3.21 per Unit) per share of common stock, an
- $0 — d to the public in this offering, minus $0.0001, and the exercise price of each Pr
- $3,2099 — ncluding one Pre-Funded Warrant will be $3,2099. (2) We have agreed to pay the placem
- $100,000 — and other out-of-pocket expenses, up to $100,000. In addition, we have agreed to issue t
- $4.0125 — nded Warrants), at an exercise price of $4.0125 per share, which represents 125% of the
- $8 million — ains. In December 2020, Bayer purchased $8 million of our Series B preferred stock, which
Filing Documents
- forms-1.htm (S-1) — 566KB
- ex1-1.htm (EX-1.1) — 134KB
- ex4-6.htm (EX-4.6) — 142KB
- ex4-7.htm (EX-4.7) — 127KB
- ex4-8.htm (EX-4.8) — 124KB
- ex4-9.htm (EX-4.9) — 111KB
- ex5-1.htm (EX-5.1) — 11KB
- ex10-7.htm (EX-10.7) — 255KB
- ex23-2.htm (EX-23.2) — 4KB
- ex107.htm (EX-FILING FEES) — 47KB
- ex23-2_001.jpg (GRAPHIC) — 11KB
- ex23-2_002.jpg (GRAPHIC) — 7KB
- ex23-2_003.jpg (GRAPHIC) — 17KB
- logo_001.jpg (GRAPHIC) — 12KB
- forms-1_001.jpg (GRAPHIC) — 27KB
- 0001493152-24-027219.txt ( ) — 1625KB
RISK FACTORS
RISK FACTORS 8 SUMMARY FINANCIAL DATA 9 RISK FACTORS 10 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 14 TRADEMARKS, SERVICE MARKS AND TRADE NAMES 15 USE OF PROCEEDS 16 DIVIDEND POLICY 17 CAPITALIZATION 18 DESCRIPTION OF SECURITIES 19 SHARES ELIGIBLE FOR FUTURE SALE 26 PLAN OF DISTRIBUTION 27 LEGAL MATTERS 31 EXPERTS 31 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 31 WHERE YOU CAN FIND MORE INFORMATION 31 You should rely only on the information contained in this prospectus or incorporated by reference. We have not authorized any other person to provide you with information different from or in addition to that contained in this prospectus, and we take no responsibility for any other information others may give you. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. Except as otherwise stated, you should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus and that the information in any report incorporated by reference is accurate only as of the date of such report. Our business, financial condition, results of operations and prospects may have changed since such dates. No action is being taken in any jurisdiction outside the United States to permit a public offering of our securities or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus applicable to that jurisdiction. As used in this prospectus, unless the context indicates or otherwise requires, “the Company,” “our Company,” “we,” “us,” and &ld